Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors
暂无分享,去创建一个
S. Fosså | C. Kiserud | H. Haugnes | A. Dahl | M. Brydøy | T. Tandstad | L. Thorsen | T. Myklebust | R. Hellesnes
[1] S. Fosså,et al. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Gupta,et al. Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Gopal K Singh,et al. The Association Between Psychological Distress and Cancer Mortality in the United States: Results from the 1997-2014 NHIS-NDI Record Linkage Study. , 2021, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[4] G. Daugaard,et al. Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study , 2020, Journal of Cancer Survivorship.
[5] S. Schlesinger,et al. Dose–response relationship between physical activity and mortality in adults with noncommunicable diseases: a systematic review and meta-analysis of prospective observational studies , 2020, International Journal of Behavioral Nutrition and Physical Activity.
[6] C. Otte,et al. Comorbid depression in medical diseases , 2020, Nature Reviews Disease Primers.
[7] M. Taphoorn,et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up†. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Thomas J. Smith,et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Fosså,et al. Risk of positive selection bias in longitudinal surveys among cancer survivors: Lessons learnt from the national Norwegian Testicular Cancer Survivor Study. , 2020, Cancer epidemiology.
[10] S. Fosså,et al. Continuing increased risk of second cancer in long‐term testicular cancer survivors after treatment in the cisplatin era , 2020, International journal of cancer.
[11] S. Fosså,et al. Thromboembolic events after high‐intensity training during cisplatin‐based chemotherapy for testicular cancer: Case reports and review of the literature , 2020, International journal of cancer.
[12] Chad A. LaGrange,et al. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[13] C. Johansen,et al. Psychological stress in long-term testicular cancer survivors: a Danish nationwide cohort study , 2019, Journal of Cancer Survivorship.
[14] J. Witjes,et al. Platinum exposure and cause‐specific mortality among patients with testicular cancer , 2019, Cancer.
[15] C. Matthews,et al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable , 2019, Medicine and science in sports and exercise.
[16] S. Katikireddi,et al. Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority , 2019, BMC Cancer.
[17] F. Saad,et al. Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis , 2019, World Journal of Urology.
[18] P. Nathan,et al. Association of Exercise With Mortality in Adult Survivors of Childhood Cancer , 2018, JAMA oncology.
[19] J. Witjes,et al. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Berney,et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] K. Courneya,et al. Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors , 2018, British Journal of Cancer.
[22] S. Fosså,et al. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Fosså,et al. Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors , 2018, Advances in urology.
[24] C. Johansen,et al. The Hospital Anxiety and Depression Scale (HADS) and the 9‐item Patient Health Questionnaire (PHQ‐9) as screening instruments for depression in patients with cancer , 2017, Cancer.
[25] G David Batty,et al. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies , 2017, British Medical Journal.
[26] C. Johansen,et al. Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study. , 2016, JAMA oncology.
[27] C. Bokemeyer,et al. Symptom burden in long-term germ cell tumor survivors , 2016, Supportive Care in Cancer.
[28] M. Stockler,et al. The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study , 2016, Journal of Cancer Survivorship.
[29] S. Fosså,et al. Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[30] S. Fosså,et al. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] S. Fosså,et al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] F. Mols,et al. Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry , 2013, Journal of Cancer Survivorship.
[33] M. Vercelli,et al. Socio-economic inequalities: a review of methodological issues and the relationships with cancer survival. , 2013, Critical reviews in oncology/hematology.
[34] S. Fosså,et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] B. Nes,et al. Exercise patterns and peak oxygen uptake in a healthy population: the HUNT study. , 2012, Medicine and science in sports and exercise.
[36] K. Schmitz,et al. Cancer, physical activity, and exercise. , 2012, Comprehensive Physiology.
[37] Sameer M. Siddiqi,et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.
[38] S. Palmer,et al. Health behaviors among testicular cancer survivors. , 2012, The Journal of community and supportive oncology.
[39] A. Sood,et al. Biobehavioral Factors and Cancer Progression: Physiological Pathways and Mechanisms , 2011, Psychosomatic medicine.
[40] M. Ro̸rth,et al. Progressive Resistance Training and Cancer Testis (PROTRACT) - Efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial , 2011, BMC Cancer.
[41] A. Mykletun,et al. Concurrent validity of the CAGE questionnaire. The Nord-Trøndelag Health Study. , 2011, Addictive behaviors.
[42] R. Souchon,et al. Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Testicular Germ Cell Cancer Patients , 2011, Oncology Research and Treatment.
[43] E. Weiderpass. Lifestyle and cancer risk. , 2010, Journal of preventive medicine and public health = Yebang Uihakhoe chi.
[44] P. Spiess,et al. Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] R. Bremnes,et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Gospodarowicz. Testicular cancer patients: considerations in long-term follow-up. , 2008, Hematology/oncology clinics of North America.
[47] S. Fosså,et al. Scale for Chemotherapy-induced Long-term Neurotoxicity (SCIN): Psychometrics, Validation, and Findings in a Large Sample of Testicular Cancer Survivors , 2006, Quality of Life Research.
[48] G. Rustin,et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial , 2005, The Lancet.
[49] D. Dearnaley,et al. Fertility, gonadal and sexual function in survivors of testicular cancer , 2005, British Journal of Cancer.
[50] M. Williams,et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17) , 2005, British Journal of Cancer.
[51] A. Mykletun,et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] A. Mykletun,et al. Depression in relation to age and gender in the general population: the Nord‐Trøndelag Health Study (HUNT) , 2001, Acta psychiatrica Scandinavica.
[53] A. Gulsvik,et al. Cigarette smoking gives more respiratory symptoms among women than among men The Nord-Trøndelag Health Study (HUNT) , 2000, Journal of epidemiology and community health.
[54] S. Fosså,et al. A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma , 2000, British Journal of Cancer.
[55] E. Arnesen,et al. Impact of body weight on blood pressure with a focus on sex differences: the Tromso Study, 1986-1995. , 2000, Archives of internal medicine.
[56] R Sylvester,et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] L. Collette,et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] S. Fosså,et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] M. Williams,et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] S. Fosså,et al. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. , 1995, British Journal of Cancer.
[61] S. Fosså,et al. Original article: BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours , 1991 .
[62] S. Fosså,et al. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. , 1989, The Journal of urology.
[63] L. Einhorn,et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.
[64] J. Ewing,et al. Detecting alcoholism. The CAGE questionnaire. , 1984, JAMA.
[65] R. Snaith,et al. The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.
[66] L. Einhorn. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. , 1981, Cancer research.
[67] A. Barrett,et al. COMBINED MANAGEMENT OF MALIGNANT TERATOMA OF THE TESTIS , 1979, The Lancet.
[68] S. Rossetti,et al. Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review. , 2018, European review for medical and pharmacological sciences.
[69] L. Sheppard,et al. Contribution of health behaviors to the association between area-level socioeconomic status and cancer mortality. , 2016, Social science & medicine.
[70] Arnulf Langhammer,et al. The Nord-Trøndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation , 2003 .
[71] G. Mead,et al. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).
[72] S. Fosså,et al. Management of patients with poor-prognosis nonseminomatous germ cell cancer. , 1990, Oncology.
[73] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[74] S. Fosså,et al. Unilateral retroperitoneal lymph node dissection in patients with non-seminomatous testicular tumor in clinical stage I. , 1984, European urology.